Join
Live feed
·
PRReleasevia Quantisnow
Cardiff Oncology Inc. logo

Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
CRDF· Cardiff Oncology Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CRDF (Cardiff Oncology Inc.) and more on Quantisnow.